BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for advanced Hodgkin's lymphoma, in place of the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned / S. Viviani, P.L. Zinzani, A. Rambaldi, E. Brusamolino, A. Levis, V. Bonfante, U. Vitolo, A. Pulsoni, A.M. Liberati, G. Specchia, P. Valagussa, A. Rossi, F. Zaja, E.M. Pogliani, P. Pregno, M. Gotti, A. Gallamini, D. Rota Scalabrini, G. Bonadonna, A. Gianni. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 365:3(2011 Jul 21), pp. 203-212. [10.1056/NEJMoa1100340]
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
A. Rambaldi;A. Gianni
2011
Abstract
BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for advanced Hodgkin's lymphoma, in place of the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.